Novo Nordisk A/S reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was DKK 176,954 million compared to DKK 140,800 million a year ago. Net income was DKK 55,525 million compared to DKK 47,757 million a year ago.

Basic earnings per share from continuing operations was DKK 12.255 compared to DKK 10.395 a year ago. Diluted earnings per share from continuing operations was DKK 12.22 compared to DKK 10.37 a year ago.